NASDAQ$IRMD
IRadimed Corporation · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
IRadimed reported record revenue and increased profitability in Q2 2022.
IRadimed Corporation announced its Q2 2022 financial results, reporting record revenue of $12.7 million, a GAAP diluted EPS of $0.26, and a non-GAAP diluted EPS of $0.26. The company's orders exceeded shipments, resulting in a strong backlog entering the second half of the year.
- Reported highest ever revenue quarter and third consecutive quarter of record revenues.
- Orders booked in the quarter exceeded shipments, providing a strong backlog.
- Domestic sales accounted for 85.0% of total revenue.
- Gross profit margin was 79.7%.
Headline financials
Revenue & EPS history
IRadimed · Revenue · Quarterly
$12.7M
Forward guidance
For the third quarter 2022, the Company expects to report revenue of $13.1 million to $13.3 million, GAAP diluted earnings per share of $0.21 to $0.24, and non-GAAP diluted earnings per share of $0.22 to $0.25.
Tailwinds
- Expects revenue of $13.1 million to $13.3 million
- GAAP diluted earnings per share of $0.21 to $0.24
- Non-GAAP diluted earnings per share of $0.22 to $0.25
- Increased full year 2022 financial guidance
- Full year 2022 revenue of $52.5 million to $53.2 million
Headwinds
- GAAP diluted earnings per share of $0.89 to $0.95
- Non-GAAP diluted earnings per share of $0.96 to $1.03
- Non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax
- Stock-based compensation expense for the third quarter 2022 is expected to be approximately $0.3 million
- Stock-based compensation expense for the full year is expected to be approximately $1.1 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+2.2%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+2.8%
Avg return
30 days after
59%
30 / 51 earnings
Positive
+32.1%
Q2 2019
Best reaction
-20.0%
Q1 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | +3.4% | +8.6% | |
| Q4 2025 | +9.6% | +4.0% | +3.5% | |
| Q3 2025 | +9.4% | +9.8% | +21.3% | |
| Q1 2025 | -2.3% | -3.0% | +13.7% | |
| Q4 2024 | -8.4% | -5.8% | -13.3% | |
| Q3 2024 | -8.8% | -0.4% | +1.9% | |
| Q2 2024 | -4.9% | -6.6% | +0.5% | |
| Q1 2024 | +6.4% | +4.0% | +1.1% | |
| Q4 2023 | -6.9% | -3.3% | -5.2% | |
| Q3 2023 | +3.5% | -1.3% | +3.5% | |
| Q2 2023 | +10.7% | +10.4% | +9.7% | |
| Q1 2023 | +8.5% | +8.3% | +13.0% | |
| Q4 2022 | +10.1% | -0.3% | +3.7% | |
| Q3 2022 | +5.2% | +6.0% | +9.4% | |
| Q2 2022 | -1.4% | -3.2% | -17.8% | |
| Q1 2022 | -17.2% | -21.5% | -19.4% | |
| Q4 2021 | +19.8% | +33.5% | +24.1% | |
| Q3 2021 | +6.4% | +5.1% | +16.8% | |
| Q2 2021 | +1.0% | -1.8% | -2.2% | |
| Q1 2021 | +5.9% | +9.2% | +3.9% | |
| Q4 2020 | -7.2% | -2.4% | -7.8% | |
| Q3 2020 | +3.1% | +2.7% | +9.0% | |
| Q2 2020 | -4.2% | -2.7% | -7.2% | |
| Q1 2020 | -7.9% | -8.4% | +8.1% | |
| Q4 2019 | +2.4% | -0.5% | -10.8% | |
| Q3 2019 | +5.5% | +1.9% | -8.2% | |
| Q2 2019 | +32.1% | +23.6% | +7.1% | |
| Q1 2019 | -20.0% | -15.1% | -25.3% | |
| Q4 2018 | -0.4% | -0.9% | -12.4% | |
| Q3 2018 | +1.7% | +4.8% | +16.1% | |
| Q2 2018 | +4.6% | +9.8% | +17.5% | |
| Q1 2018 | +13.6% | +15.1% | +17.0% | |
| Q4 2017 | -6.3% | -7.3% | -13.6% | |
| Q3 2017 | +12.2% | +7.1% | +11.0% | |
| Q2 2017 | +17.3% | +14.9% | +18.5% | |
| Q1 2017 | -3.4% | -3.4% | -6.2% | |
| Q4 2016 | -4.0% | -2.8% | -2.8% | |
| Q3 2016 | +2.2% | +0.5% | +22.7% | |
| Q2 2016 | +2.8% | -4.6% | -1.2% | |
| Q1 2016 | -5.6% | — | — | |
| Q4 2015 | -17.1% | — | — | |
| Q3 2015 | +11.6% | — | — | |
| Q1 2014 | +0.2% | — | — | |
| Q2 2015 | +18.6% | — | — | |
| Q1 2015 | +2.2% | — | — | |
| Q4 2014 | +7.2% | — | — | |
| Q3 2013 | +4.9% | — | — | |
| Q3 2014 | +4.9% | — | — | |
| Q4 2013 | -2.3% | — | — | |
| Q2 2013 | -2.3% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro